Physician profile
Anthony King
NPI 1194700104
$19,317.18
in general payments reported to CMS, 2019-2025
19 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $681 · 2021: $1,076 · 2022: $672 · 2023: $1,513 · 2024: $266 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940 · Education: $6.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.86 |
| Education | $6.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,849.52 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $3,685.05 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $832.68 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $731.66 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $669.94 | 2019-2023 | Jardiance |
| Abbott Laboratories | $510.62 | 2019-2023 | Cardiomems |
| Amgen INC. | $478.39 | 2019-2024 | Repatha |
| Pfizer INC. | $320.33 | 2019-2020 | |
| Abiomed | $302.98 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.66 | 2022-2023 | Lifevest |
| Vifor Pharma, INC. | $118.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.77 | 2023 | |
| Amarin Pharma, INC. | $102.47 | 2020 | |
| Alnylam Pharmaceuticals INC. | $95.04 | 2023 | Onpattro |
| Medtronic Vascular, INC. | $90.19 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $86.00 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $81.99 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.01 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.